top of page
Image by Warren Umoh
Screenshot 2024-09-15 at 19.19.40.png
image.png

GENOUS™ SUCCESS STORY

Targeted Therapy Success in a 44-Year-Old Male with Pilocytic Astrocytom

CHALLENGE

The discovery of the BRAF-KIAA1549 rearrangement in tumors has highlighted the need for targeted therapy. However, without extensive genetic testing, finding the right treatment for a patient is a difficult hurdle.

Diagnosed with pilocytic astrocytoma, a slow-growing brain tumor, a 44-year-old man faced a challenging treatment journey. After surgery, he began the Stupp protocol—a standard regimen of chemotherapy and radiation.

Screenshot 2024-09-15 at 19.19.57.png

THE PRECISION ONCOLOGY SOLUTION

The molecular tumor board team conducted local molecular testing, which confirmed the presence of the BRAF-KIAA1549 rearrangement in the patient’s tumor. Although they didn’t have the full genetic profile, they turned to Genomate® for guidance. The Genomate Report suggested a promising option: Selumetinib, a drug that targets the MEK pathway. Even though it wasn’t specifically approved for his type of tumor, the evidence was strong enough to consider it. Based on the findings, off-label use was secured for the patient.

THE RIGHT DRUG. THE FIRST TIME. EVERY TIME

The patient responded well to Selumetinib, with tumor stability maintained for over a year. This case shows how precision oncology, combined with expert medical care, can guide the right decisions—even when full genetic information isn’t available.
For the treating team  it translated into:

  • Higher success rate

  • Faster decision making

  • Eliminating the guesswork and side effects

  • Giving the patient the best fighting chance

OUTCOME AND IMPACT OF TARGETED THERAPY

bottom of page